In this exclusive interview Alexander Zhavoronkov reveals how Insilico’s AI-designed drug reached Phase II trials, why end-to-end automation and robotics are reshaping R&D, and what it takes to build a culture where AI engineers and biologists co-create. Explore insights on platform vs. pipeline strategy, longevity as a business case, and the next decade of AI-driven pharma innovation.
Topics:
- From Hype to P&L Impact
- The “Fully Generative” Drug in Phase II
- Platform vs. Pipeline Strategy
- Data Advantage and Ecosystem Positioning
- Robotics and End-to-End Automation
- Rethinking Clinical Development with AI
- Longevity and Aging as a Business Case
- Talent and Culture in AI-Native Biotech
- The Next 10 Years of AI in Pharma